Unrelated cord blood compared with haploidentical grafts in patients with hematological malignancies

Cancer

Volumn 121, Issue 11, 2015, Pages 1809-1816

  El Cheikh, Jean ^a   Crocchiolo, Roberto ^b   Furst, Sabine ^a   Bramanti, Stefania ^b   Sarina, Barbara ^b   Granata, Angela ^a   Vai, Andrea ^b   Lemarie, Claude ^a   Faucher, Catherine ^a   Mohty, Bilal ^a   Harbi, Samia ^a,c   Bouabdallah, Reda ^a   Vey, Norbert ^a,c,d   Santoro, Armando ^c   Chabannon, Christian ^a,c,d   Castagna, Luca ^a,b   Blaise, Didier ^a,c,d  

^a INSTITUT PAOLI CALMETTES   (France)

^b HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^c AIX MARSEILLE UNIVERSITY   (France)

^d AIX MARSEILLE UNIVERSITY   (France)

Author keywords

allogeneic hematopoietic stem cell transplantation; haploidentical donor; high risk hematological diseases; nonmyeloablative conditioning regimen; unrelated umbilical cord blood

Indexed keywords

ACICLOVIR; CASPOFUNGIN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FLUCONAZOLE; FLUDARABINE; FOSCARNET; GANCICLOVIR; ITRACONAZOLE; LEVOFLOXACIN;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BLOOD DONOR; CHRONIC GRAFT VERSUS HOST DISEASE; CONTROLLED STUDY; FEMALE; FRANCE; HAPLOIDENTICAL DONOR; HEMATOLOGIC MALIGNANCY; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALE; MORTALITY; MYCOSIS; NONHUMAN; NONRECURRENCE MORTALITY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; UMBILICAL CORD BLOOD; UNRELATED DONORS; VIRUS INFECTION; WHOLE BODY RADIATION; ALLOTRANSPLANTATION; CLINICAL TRIAL; CORD BLOOD STEM CELL TRANSPLANTATION; FETUS BLOOD; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY TEST; IMMUNOSUPPRESSIVE TREATMENT; MIDDLE AGED; MULTICENTER STUDY; PROCEDURES; YOUNG ADULT;

ADULT; AGED; CORD BLOOD STEM CELL TRANSPLANTATION; FEMALE; FETAL BLOOD; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY TESTING; HUMANS; MALE; MIDDLE AGED; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; UNRELATED DONORS; YOUNG ADULT;

EID: 84929656135     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.29271     Document Type: Article

References (34)

1. Copelan EA,. Hematopoietic stem-cell transplantation. N Engl J Med. 2006; 354: 1813-1826.
2. Hansen JA, Petersdorf E, Martin PJ, Anasetti C,. Hematopoietic stem cell transplants from unrelated donors. Immunol Rev. 1997; 157: 141-151.
3. Huang XJ,. HLA-mismatched/haploidentical hematopoietic stem cell transplantation: a field in which Chinese doctors are making great contributions. Chin Med J (Engl). 2010; 123: 1235-1240.
4. Rocha V, Labopin M, Sanz G, et al,; Acute Leukemia Working Party of European Blood and Marrow Transplant Group; Eurocord-Netcord Registry. Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia. N Engl J Med. 2004; 351: 2276-2285.
5. Rocha V, Gluckman E,; Eurocord-Netcord Registry and European Blood and Marrow Transplant Group. Improving outcomes of cord blood transplantation: HLA matching, cell dose and other graft- and transplantation-related factors. Br J Haematol. 2009; 147: 262-274.
6. Eapen M, Rocha V, Sanz G, et al,; Center for International Blood and Marrow Transplant Research; Acute Leukemia Working Party Eurocord (the European Group for Blood Marrow Transplantation); National Cord Blood Program of the New York Blood Center. Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis. Lancet Oncol. 2010; 11: 653-660.
7. Lee EJ, Han JY, Lee JW, et al., Outcome of allogeneic hematopoietic stem cell transplantation for childhood acute lymphoblastic leukemia in second complete remission: a single institution study. Korean J Pediatr. 2012; 55: 100-106.
8. Woolfrey A, Klein JP, Haagenson M, et al., HLA-C antigen mismatch is associated with worse outcome in unrelated donor peripheral blood stem cell transplantation. Biol Blood Marrow Transplant. 2011; 17: 885-892.
9. Finke J, Schmoor C, Lang H, Potthoff K, Bertz H,. Matched and mismatched allogeneic stem-cell transplantation from unrelated donors using combined graft-versus-host disease prophylaxis including rabbit anti-T lymphocyte globulin. J Clin Oncol. 2003; 21: 506-513.
10. Kroger N, Zabelina T, Kruger W, et al., In vivo T cell depletion with pretransplant anti-thymocyte globulin reduces graft-versus-host disease without increasing relapse in good risk myeloid leukemia patients after stem cell transplantation from matched related donors. Bone Marrow Transplant. 2002; 29: 683-689.
11. Alshemmari S, Ameen R, Gaziev J,. Haploidentical hematopoietic stem-cell transplantation in adults. Bone Marrow Res 2011; 2011: 303487.
12. Aversa F, Terenzi A, Felicini R, et al., Haploidentical stem cell transplantation for acute leukemia. Int J Hematol. 2002; 76 (suppl 1): 165-168.
13. Palma J, Salas L, Carrion F, et al., Haploidentical stem cell transplantation for children with high-risk leukemia. Pediatr Blood Cancer. 2012; 59: 895-901.
14. Solomon SR, Sizemore CA, Sanacore M, et al., Haploidentical transplantation using T cell replete peripheral blood stem cells and myeloablative conditioning in patients with high-risk hematologic malignancies who lack conventional donors is well tolerated and produces excellent relapse-free survival: results of a prospective phase II trial. Biol Blood Marrow Transplant. 2012; 18: 1859-1866.
15. Fuchs EJ, Huang XJ, Miller JS,. HLA-haploidentical stem cell transplantation for hematologic malignancies. Biol Blood Marrow Transplant. 2010; 16 (suppl 1): S57-S63.
16. Luznik L, O'Donnell PV, Fuchs EJ,. Post-transplantation cyclophosphamide for tolerance induction in HLA-haploidentical bone marrow transplantation. Semin Oncol. 2012; 39: 683-693.
17. Luznik L, O'Donnell PV, Symons HJ, et al., HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2008; 14: 641-650.
18. Luznik L, Fuchs EJ,. High-dose, post-transplantation cyclophosphamide to promote graft-host tolerance after allogeneic hematopoietic stem cell transplantation. Immunol Res. 2010; 47: 65-77.
19. Luznik L, Jones RJ, Fuchs EJ,. High-dose cyclophosphamide for graft-versus-host disease prevention. Curr Opin Hematol. 2010; 17: 493-499.
20. Barker JN, Weisdorf DJ, DeFor TE, Blazar BR, Miller JS, Wagner JE,. Rapid and complete donor chimerism in adult recipients of unrelated donor umbilical cord blood transplantation after reduced-intensity conditioning. Blood. 2003; 102: 1915-1919.
21. Flowers ME, Kansu E, Sullivan KM,. Pathophysiology and treatment of graft-versus-host disease. Hematol Oncol Clin North Am. 1999; 13: 1091-1112, viii-ix.
22. Przepiorka D, Weisdorf D, Martin P, et al., 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant. 1995; 15: 825-828.
23. Armand P, Gibson CJ, Cutler C, et al., A disease risk index for patients undergoing allogeneic stem cell transplantation. Blood. 2012; 120: 905-913.
24. Aversa F, Terenzi A, Tabilio A, et al., Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. J Clin Oncol. 2005; 23: 3447-3454.
25. Aversa F,. Haploidentical haematopoietic stem cell transplantation for acute leukaemia in adults: experience in Europe and the United States. Bone Marrow Transplant. 2008; 41: 473-481.
26. Huang XJ,. Haploidentical hematopoietic stem cell transplantation without in vitro T-cell-depletion for the treatment of hematologic diseases. Chimerism. 2013; 4: 26-28.
27. Huang XJ, Liu DH, Liu KY, et al., Haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion for the treatment of hematological malignancies. Bone Marrow Transplant. 2006; 38: 291-297.
28. Fuchs EJ,. Haploidentical transplantation for hematologic malignancies: where do we stand? Hematology Am Soc Hematol Educ Program. 2012; 2012: 230-236.
29. Brunstein CG, Fuchs EJ, Carter SL, et al,; Blood and Marrow Transplant Clinical Trials Network. Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts. Blood. 2011; 118: 282-288.
30. Raiola AM, Dominietto A, Di Grazia C, et al., Unmanipulated haploidentical transplants compared with other alternative donors and matched sibling grafts. Biol Blood Marrow Transplant. 2014; 20: 1573-1579.
31. Luznik L, Bolanos-Meade J, Zahurak M, et al., High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease. Blood. 2010; 115: 3224-3230.
32. Kanakry CG, O'Donnell PV, Furlong T, et al., Multi-institutional study of post-transplantation cyclophosphamide as single-agent graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation using myeloablative busulfan and fludarabine conditioning. J Clin Oncol. 2014; 32: 3497-3505.
33. Castagna L, Crocchiolo R, Furst S, et al., Bone marrow compared with peripheral blood stem cells for haploidentical transplantation with a nonmyeloablative conditioning regimen and post-transplantation cyclophosphamide. Biol Blood Marrow Transplant. 2014; 20: 724-729.
34. Raj K, Pagliuca A, Bradstock K, et al., Peripheral blood hematopoietic stem cells for transplantation of hematological diseases from related, haploidentical donors after reduced-intensity conditioning. Biol Blood Marrow Transplant. 2014; 20: 890-895.